Publikationen in Zusammenarbeit mit Forschern von King's College Hospital (22)

2024

  1. Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey

    Infection

  2. Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the EPICOVIDEHA registry

    Hematological Oncology, Vol. 42, Núm. 1

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings

    International Journal of Infectious Diseases, Vol. 137, pp. 98-110

  3. COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)

    Haematologica, Vol. 108, Núm. 1, pp. 22-33

  4. Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey

    Blood Advances, Vol. 7, Núm. 11, pp. 2645-2655

  5. Randomised trial of genetic testing and targeted intervention to prevent the development and progression of Paget’s disease of bone

    Annals of the Rheumatic Diseases, Vol. 83, Núm. 4, pp. 529-536

2022

  1. B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)

    Frontiers in Oncology, Vol. 12

  2. COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP

    Blood Advances, Vol. 6, Núm. 7, pp. 2427-2433

  3. MDS-110 SELECT-MDS-1 Trial in Progress: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tamibarotene/Azacitidine Versus Placebo/Azacitidine in Newly Diagnosed Adult Patients Selected for RARA-Positive Higher-Risk MDS

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S303-S304

2021

  1. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

    Journal of Hematology and Oncology, Vol. 14, Núm. 1

  2. Impact of Bacillus Calmette-Gue´rin (BCG) vaccination on postoperative mortality in patients with perioperative SARS-CoV-2 infection

    BJS Open

  3. Machine learning risk prediction of mortality for patients undergoing surgery with perioperative SARS-CoV-2: The COVIDSurg mortality score

    British Journal of Surgery, Vol. 19, Núm. 4

2019

  1. Zoledronate in the prevention of Paget's (ZiPP): Protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to prevent SQSTM1-mediated Paget's disease of bone

    BMJ Open, Vol. 9, Núm. 9

2017

  1. Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group

    Haematologica, Vol. 102, Núm. 2, pp. 308-319

2014

  1. Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: A subset analysis from the MDS-004 study

    European Journal of Haematology, Vol. 93, Núm. 5, pp. 429-438

  2. Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes - Proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS

    Leukemia, Vol. 28, Núm. 9, pp. 1793-1798

2013

  1. Diagnosis and treatment of primary myelodysplastic syndromes in adults: Recommendations from the European LeukemiaNet

    Blood, Vol. 122, Núm. 17, pp. 2943-2964

  2. Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: Position paper of an International Consortium and the European LeukemiaNet Working Group

    Leukemia and Lymphoma, Vol. 54, Núm. 3, pp. 472-475

2011

  1. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

    Blood, Vol. 118, Núm. 14, pp. 3765-3776